How to ‘drug’ our way out of the obesity crisis (or not): the roll-out of semaglutide
British Journal of General Practice · 2024-05 · 74 (742) · 218-218
DOI: 10.3399/bjgp24x737241 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of General Practice, online erschienen am 25.04.2024. Verfasst von Nada Khan. Beteiligte Einrichtung: Nada is an Exeter-based GP and clinical academic, and an Associate Editor at the BJGP. Email: nadakhan@nhs.net. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nada is an Exeter-based GP and clinical academic, and an Associate Editor at the BJGP. Email: nadakhan@nhs.net.
Zitieren
APA
Khan, N. (2024). How to ‘drug’ our way out of the obesity crisis (or not): the roll-out of semaglutide. British Journal of General Practice, 74(742), 218-218. https://doi.org/10.3399/bjgp24x737241
Vancouver
Khan N. How to ‘drug’ our way out of the obesity crisis (or not): the roll-out of semaglutide. British Journal of General Practice. 2024;74(742):218-218. doi:10.3399/bjgp24x737241
BibTeX
@article{Khan2024,
author = {Khan, Nada},
title = {How to ‘drug’ our way out of the obesity crisis (or not): the roll-out of semaglutide},
journal = {British Journal of General Practice},
year = {2024},
volume = {74},
number = {742},
pages = {218--218},
doi = {10.3399/bjgp24x737241}
}
EUVIMED